FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Biblioteca de Peptidos

Matrixyl

Palmitoyl Pentapeptide-4 / Pal-KTTKS

Beauty & Skincare

Matrixyl (Palmitoyl Pentapeptide-4, also known as pal-KTTKS) is a cosmetic peptide consisting of a palmitoyl group attached to the pentapeptide lysine-threonine-threonine-lysine-serine, designed to stimulate collagen and extracellular matrix production in dermal fibroblasts. It was developed by Sederma and is one of the most extensively studied and commercially successful topical anti-aging peptides. Matrixyl functions as a matrikine, mimicking the activity of collagen breakdown fragments to signal fibroblasts to produce new collagen, fibronectin, and glycosaminoglycans.

Mecanismo de Acción

Lipopeptide consisting of a palmitoyl group linked to the pentapeptide KTTKS (a collagen I fragment). Acts as a matrikine, signaling fibroblasts to increase collagen I, III, and IV synthesis, fibronectin production, and hyaluronic acid production via TGF-beta pathway activation.

Protocolos de Investigación

Para propósitos de investigación solo. No es asesoramiento médico.

Topical application at 2-8% concentration in serums. Applied twice daily. Synergistic with retinol and vitamin C. Results visible after 8-12 weeks of consistent use. Not injected.

Notas de Investigación

Clinical Research Status

Matrixyl has been the subject of multiple clinical studies demonstrating measurable anti-wrinkle efficacy when applied topically at concentrations of 2-5% in appropriate formulations. Double-blind placebo-controlled trials have shown statistically significant improvements in wrinkle depth, skin roughness, and overall photoaging scores after 2-4 months of regular application. It is widely incorporated into commercial skincare products and is recognized by dermatologists as one of the more evidence-based cosmetic peptides available.

Key Published Findings

In vitro studies demonstrate that Matrixyl stimulates collagen I synthesis by up to 350% and collagen IV synthesis by up to 200% in human fibroblast cultures at relevant concentrations. Clinical measurements using profilometry show wrinkle depth reduction of up to 36% after 4 months of twice-daily application in controlled studies. The palmitic acid chain enhances skin penetration and cell membrane interaction compared to the naked KTTKS peptide, which showed limited bioavailability without the lipophilic modification.

Safety Profile

Matrixyl has an excellent safety profile with no reported systemic side effects, sensitization, or phototoxicity in clinical testing, consistent with its topical application and local mechanism of action. Skin irritation is extremely rare and typically associated with other formulation ingredients rather than the peptide itself. It is considered safe for use during pregnancy and lactation at cosmetic concentrations, though formal reproductive toxicology studies have not been conducted.

Comparison to Related Compounds

Matrixyl 3000 is a newer generation product combining Matrixyl (pal-KTTKS) with palmitoyl tripeptide-1 for enhanced synergistic collagen stimulation through complementary pathways. Compared to retinoids, Matrixyl provides collagen stimulation without the associated irritation, photosensitivity, or retinization period, though efficacy is generally considered more modest. Argireline (acetyl hexapeptide-3) works through an entirely different mechanism (neuromuscular modulation) and is complementary rather than competitive with Matrixyl in anti-aging formulations.

Community Observations

Skincare enthusiasts consider Matrixyl one of the best-supported peptides for anti-aging, often incorporated into daily serums alongside vitamin C, niacinamide, and hyaluronic acid. Results are typically reported as gradual improvements in skin texture and fine line appearance over 2-3 months of consistent use. The peptide is available in numerous commercial products ranging from drugstore to luxury price points, with concentration and formulation quality varying significantly across brands.

Media Vida

N/A (topical)

Reconstitución

N/A (topical formulation)

Almacenamiento

Liofilizado

Room temperature. Stable in cosmetic formulations.

Reconstituído

Stable in formulation. Protect from excessive heat.

Estado Legal EE.UU.

Cosmetic ingredient (unregulated)

También Se Conoce Como

Palmitoyl Pentapeptide-4Pal-KTTKS

Preguntas frecuentes

¿Qué es Matrixyl?

Matrixyl (Palmitoyl Pentapeptide-4, also known as pal-KTTKS) is a cosmetic peptide consisting of a palmitoyl group attached to the pentapeptide lysine-threonine-threonine-lysine-serine, designed to stimulate collagen and extracellular matrix production in dermal fibroblasts. It was developed by Sederma and is one of the most extensively studied and commercially successful topical anti-aging peptides. Matrixyl functions as a matrikine, mimicking the activity of collagen breakdown fragments to signal fibroblasts to produce new collagen, fibronectin, and glycosaminoglycans.

¿Cómo funciona Matrixyl?

Lipopeptide consisting of a palmitoyl group linked to the pentapeptide KTTKS (a collagen I fragment). Acts as a matrikine, signaling fibroblasts to increase collagen I, III, and IV synthesis, fibronectin production, and hyaluronic acid production via TGF-beta pathway activation.

¿Cuál es el estado regulatorio de Matrixyl en EE. UU.?

Cosmetic ingredient (unregulated)

¿Cuál es la vida media de Matrixyl?

N/A (topical)

¿Qué otros nombres tiene Matrixyl?

Palmitoyl Pentapeptide-4, Pal-KTTKS

Peptide Contacts proporciona resúmenes basados en investigaciones únicamente para fines informativos. No hospedamos, distribuimos ni endosamos la documentación del proveedor. Todos los certificados de análisis, certificados GMP y comunicaciones del proveedor deben solicitarse y verificar directamente por el comprador. Nada en esta plataforma constituye asesoramiento legal, médico o profesional. Los usuarios son únicamente responsables de verificar las credenciales del proveedor y asegurarse de cumplir con todas las leyes locales, estatales y federales aplicables antes de comprar cualquier químico de investigación. El uso de esta plataforma constituye aceptación de toda la responsabilidad personal.

Leer aviso completo